Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. on November 14, 2017. The filing announces the Company's third-quarter 2017 results of operations and financial condition, along with year-to-date sales figures for its product Mytesi® (crofelemer). Mytesi is an FDA-approved anti-secretory prescription drug marketed by the Company's wholly-owned subsidiary, Napo Pharmaceuticals, Inc.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It serves as a notification that these results were announced via a press release and a conference call on November 14, 2017. Detailed financial data is contained in the attached exhibits (Exhibit 99.1 and 99.2) rather than the body of this 8-K.
Material Changes
The filing does not explicitly detail material changes versus prior periods within the text provided. It references a "company update" and the release of Q3 2017 results, but specific comparative performance metrics are not included in this summary document.
Guidance, Outlook, and Risks
Management discussed the Q3 2017 results and company update during a conference call held on November 14, 2017. The filing notes that the information contained herein and in the exhibits is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated. No specific forward-looking guidance or risk factors are detailed in the text of this 8-K.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2017 revenue and net loss figures.
- Examine Exhibit 99.2 (Conference Call Transcript) for management commentary on sales trends and future outlook.
- Verify year-to-date sales volume for Mytesi® as referenced in the announcement.
- Check subsequent filings for detailed financial statements if not fully disclosed in the press release.